Japan · Delayed Price · Currency is JPY MediciNova Company Description
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.
The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia.
The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001.
MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
| Country | United States |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Yuichi Iwaki |
Contact Details
Address: 4275 Executive Square La Jolla, Delaware 92037 United States | |
| Phone | 858 373 1500 |
| Website | medicinova.com |
Stock Details
| Ticker Symbol | 4875 |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US58468P2065 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Yuichi Iwaki | Chief Executive Officer |
| Jason Kruger | Chief Financial Officer |